Mangoceuticals Q3 2026 Results: Net Loss of $3.55M, Loss Narrows
Mangoceuticals, Inc. is a smaller reporting company and emerging growth company focused on scaling its operations and marketing its products. The filing highlights significant risks including a limited operating history, the need for additional funding, and reliance on third-party compounding pharmacies for products not approved by the FDA.
- Key figure
- Net loss $3.55M